Enabling Protein Degradation Drug Discovery

We will be attending BIO-Europe, 24-26 October in Leipzig, Germany

 

Driving DUB Drug Discovery and Development

 

As pioneers in the rapidly emerging deubiquitinase (DUB) space, Ubiquigent™ is uniquely positioned to drive forward the discovery and development of novel DUB modulators as powerful new therapeutics for areas of high unmet need.

Founded 13 years ago, Ubiquigent has cultivated an unrivalled track record and comprehensive range of services focused on the exploitation of DUBs and the ubiquitin-proteasome system (UPS). As such, we are the partner chosen by many leading industry and academic organisations to support their drug discovery programmes spanning the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis.

Alongside the delivery of specialist services to clients, we also have an internal pipeline of drug discovery programmes and are developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting PROTACs and DUBTACs, available as potential new start points for client discovery programmes through partnerships and out-licensing agreements.

If you would like to meet with us at the event, then please contact us directly here, or get in touch through the BIO-Europe Partnering System.

We are proud to announce exciting updates to our brand and website, coming soon this September. Stay tuned!